Duke-NUS Breakthrough: Unlocking Pancreatic Cancer Treatment Potential
Researchers at Duke-NUS Medical School in Singapore have made a pivotal discovery that could transform how we treat one of the most lethal forms of cancer: pancreatic ductal adenocarcinoma, commonly known as PDAC. By identifying a molecular 'switch' governed by the gene GATA6 (GATA binding protein 6), the team has revealed why some pancreatic tumors respond to chemotherapy while others resist it fiercely. This finding not only explains the cancer's notorious resistance but also points to new combination therapies that could resensitize stubborn tumors.
Pancreatic cancer strikes silently, often diagnosed at advanced stages when surgery is no longer viable. Chemotherapy, particularly gemcitabine (a nucleoside metabolic inhibitor), remains the frontline treatment, but response rates hover around 20-30 percent, with most patients succumbing within a year. The Duke-NUS study, published in the Journal of Clinical Investigation, uncovers the dynamic interplay between tumor subtypes and genetic signaling that dictates this outcome.Read the full paper here.
The Relentless Rise of Pancreatic Cancer in Singapore
In Singapore, pancreatic cancer ranks as the ninth most common malignancy but punches above its weight as the fourth leading cause of cancer death. Recent data indicate around 1,585 new cases annually among men and 1,398 among women, fueled by an aging population and rising incidences linked to diabetes, obesity, and smoking. Globally, the five-year survival rate stands at a dismal 13 percent, underscoring the urgency for breakthroughs like this one from Duke-NUS.
Singapore's National Cancer Centre Singapore (NCCS) reports that PDAC accounts for over 90 percent of pancreatic cancers here, with KRAS mutations present in nearly all cases. These mutations hyperactivate growth signals, making tumors aggressive and evasive to standard therapies. The Duke-NUS team's work shines a light on why even KRAS-mutant tumors vary in their chemo response, offering hope for precision medicine tailored to local demographics.
Duke-NUS Medical School: Singapore's Premier Research Powerhouse
Duke-NUS Medical School, a unique partnership between Duke University (USA) and the National University of Singapore (NUS), stands as Singapore's sole graduate-entry medical institution. Established in 2005, it trains clinician-scientists through a rigorous four-year MD program post-bachelor's degree, emphasizing research from day one. With over 600 faculty driving discoveries in cancer, neuroscience, and infectious diseases, Duke-NUS has positioned Singapore as a biomedical hub in Asia.
The school's Programme in Cancer & Stem Cell Biology (CSCB), home to this study, exemplifies its translational focus. Collaborations with SingHealth and A*STAR (Agency for Science, Technology and Research) accelerate bench-to-bedside progress, supported by Singapore's S$25 billion Research, Innovation and Enterprise 2025 plan.
Decoding the Subtypes: Classical vs. Basal-Like PDAC
PDAC tumors aren't monolithic; they exist in two primary transcriptional subtypes, defined by gene expression profiles:
- Classical subtype: High GATA6 expression promotes epithelial organization, structured growth, and vulnerability to gemcitabine-based chemotherapy. Patients with these tumors often see temporary tumor shrinkage.
- Basal-like (or squamous) subtype: Low GATA6 leads to mesenchymal features, invasion, and resistance to chemo. These tumors spread faster, with poorer prognosis.
The plasticity here is key—cancer cells can toggle states, explaining why initial responders relapse. GATA6 acts as the master regulator, maintaining differentiation in classical tumors.
In patient cohorts, high GATA6 correlates with longer survival and better therapy response, validating its clinical relevance.
The Villainous KRAS/ERK/JUNB Pathway
Step-by-step, here's how resistance emerges:
- KRAS oncogene mutates (G12D/V common), constitutively activating downstream ERK kinase.
- Hyperactive ERK phosphorylates JUNB transcription factor.
- JUNB binds GATA6 promoter, repressing its expression.
- GATA6 drops, triggering epithelial-to-mesenchymal transition (EMT) and basal-like shift.
- Result: Chemo-resistant tumor thrives.
This pathway, active in 95 percent of PDACs, hijacks normal cell signaling for survival. Duke-NUS researchers used CRISPR screens to pinpoint JUNB's role, confirming the cascade.
Rigorous Experiments Validate the Switch
The study employed multifaceted approaches:
- In vitro: Organoids from patient tumors treated with KRAS inhibitor (MRTX849) + MEK inhibitor (trametinib, blocks ERK). GATA6 rebounded, sensitizing to gemcitabine.
- In vivo: Patient-derived xenografts (PDX) in mice. Triple combo eradicated tumors in GATA6-high models, superior to chemo alone.
- Human data: Analyzed biopsies; low GATA6 predicted poor response.
- AI-enhanced imaging (DeeVid) quantified subtype markers.
No single method sufficed; integration proved the switch's causality.
Meet the Minds Behind the Discovery
Professor David Virshup, a pediatric gastroenterologist turned cancer expert, leads CSCB. His lab deciphers signaling in hard-to-treat cancers. First author Zheng Zhong, a postdoc, orchestrated experiments. Collaborators from UNC Chapel Hill, including Channing Der (KRAS guru), bridged basic science and models.
"This provides a molecular map for why tumors resist—and how to flip them back," says Prof. Virshup. Interim Vice-Dean Prof. Lok Sheemei adds, "Duke-NUS's clinician-scientist model accelerates such impacts."
Tailored Therapies: Charting the Path Forward
| Therapy Approach | Target | Outcome in Models |
|---|---|---|
| Gemcitabine alone | DNA synthesis | Partial response in classical |
| KRASi + MEKi | KRAS/ERK | GATA6 restoration |
| Triple combo | All above | Tumor elimination |
KRAS inhibitors like sotorasib (FDA-approved for lung) enter PDAC trials. Duke-NUS eyes combos for Singapore's patients. Biomarker testing for GATA6 could personalize care.Duke-NUS press release.
Singapore's War on Cancer: Biomedical Momentum
Singapore invests heavily: National Precision Medicine (NPM) program sequences 100,000 genomes; Cancer Research Singapore funds translation. Duke-NUS/NCCS trials test KRAS therapies. Aging demographics (20% over 65 by 2030) demand solutions; this switch fits perfectly.
Beyond PDAC: Lessons for Other Cancers
KRAS drives 30% cancers (lung, colon). Subtype plasticity appears elsewhere; GATA6 modulation could apply. Virshup's team explores Wnt resistance in colorectal too.
Careers in Singapore's Thriving Biomedical Sector
Duke-NUS offers PhD/MD-PhD tracks, postdocs in CSCB. Singapore's EDB attracts talent with grants, visas. Roles in genomics, immunotherapy abound at A*STAR, NUS.
This discovery exemplifies why Singapore leads Asia's research: collaborative, innovative, patient-focused.
Photo by Karl Solano on Unsplash
